email article
More than 40% of patients with advanced cholangiocarcinoma (CCA) had objective responses that were durable in most cases following treatment with a multitargeted fibroblast growth factor receptor (FGFR) inhibitor, a preliminary study showed.
Treatment with the investigational agent futibatinib led to an overall response rate (ORR) of 41.7% in 103 patients and a median duration of response of 9.7 months. Another 40% of the patients had stable disease.
Median overall survival (OS) approached 2 years, and 72% of the patients were alive at 12 months, reported Lipika Goyal, MD, of Massachusetts General Hospital Cancer Center in Boston, at the American Association for Cancer Research (AACR) virtual meeting.
Immune-boosting drug may help before lung cancer surgery | iNFOnews | Thompson-Okanagan s News Source infotel.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from infotel.ca Daily Mail and Mail on Sunday newspapers.
Therapeutic cancer vaccine shows promise against multiple tumor types
By (0)
A personalized vaccine that teaches the immune system to target cancer cells was shown to be safe and feasible in a small trial, according to a new study. Photo by Belova59/Pixabay
Marc Baum went through all the usual steps to treat his bladder cancer a couple of surgeries, radiation therapy and chemotherapy, all in a three-month period.
But doctors hope that an extra step an experimental vaccine will be what keeps Baum s cancer from coming back.
Advertisement
A vaccine that uses genetics to teach a person s immune system how to precisely target the cancer has proven safe and feasible in early clinical trials, according to results just reported at the American Association for Cancer Research s annual meeting.
Lilly’s RET inhibitor Retevmo shows early promise in new cancer types
Trial included patients with pancreatic, colon, breast and salivary cancer
Eli Lilly has revealed new early-stage data for its RET inhibitor Retevmo in new cancer types, as the company looks beyond the drug’s approved lung and thyroid cancer indications.
The phase 1/2 LIBRETTO-001 trial – presented at the virtual American Association for Cancer Research (AACR) annual meeting – enrolled 32 patients with 12 unique RET fusion-positive advanced cancer types, including pancreatic, colon, breast and salivary cancer, with 62.5% having gastrointestinal tumours.
Across all 32 patients who received Retevmo (selpercatinib), the researchers observed a confirmed objective response rate (ORR) of 47%, with the median duration of response not yet reach with a follow-up of 13 months.
Study suggests common drug could be used to prevent certain skin cancers eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.